Overview

Properties

Applications

Our Abpromise guarantee covers the use of ab125156 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/2000. Predicted molecular weight: 40 kDa.
ICC/IF 1/200 - 1/1000.

Target

  • FunctionBinds to transferrin receptor (TFR) and reduces its affinity for iron-loaded transferrin.
  • Tissue specificityExpressed in all tissues tested except brain.
  • Involvement in diseaseDefects in HFE are a cause of hemochromatosis (HFE) [MIM:235200]. A disorder of iron metabolism characterized by iron overload. Excess iron is deposited in a variety of organs leading to their failure, and resulting in serious illnesses including cirrhosis, hepatomas, diabetes, cardiomyopathy, arthritis, and hypogonadotropic hypogonadism. Severe effects of the disease usually do not appear until after decades of progressive iron loading.
    Defects in HFE are associated with variegate porphyria (VP) [MIM:176200]. Porphyrias are inherited defects in the biosynthesis of heme, resulting in the accumulation and increased excretion of porphyrins or porphyrin precursors. They are classified as erythropoietic or hepatic, depending on whether the enzyme deficiency occurs in red blood cells or in the liver. VP is the most common form of porphyria in South Africa. It is characterized by skin hyperpigmentation and hypertrichosis, abdominal pain, tachycardia, hypertension and neuromuscular disturbances. High fecal levels of protoporphyrin and coproporphyrin, increased urine uroporphyrins and iron overload are typical markers of the disease. Note=Iron overload due to HFE mutations is a precipitating or exacerbating factor in variegate porphyria.
    Defects in HFE are associated with susceptibility to microvascular complications of diabetes type 7 (MVCD7) [MIM:612635]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
  • Sequence similaritiesBelongs to the MHC class I family.
    Contains 1 Ig-like C1-type (immunoglobulin-like) domain.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • dJ221C16.10.1 antibody
    • Hemochromatosis antibody
    • Hemochromatosis protein antibody
    • Hereditary hemochromatosis protein antibody
    • Hereditary hemochromatosis protein HLA H antibody
    • HFE 1 antibody
    • HFE antibody
    • HFE_HUMAN antibody
    • HFE1 antibody
    • HH antibody
    • High Fe antibody
    • HLA H antibody
    • HLA-H antibody
    • HLAH antibody
    • MGC:150812 antibody
    • MGC10379 antibody
    • MGC103790 antibody
    • MHC class I like protein HFE antibody
    • MVCD7 antibody
    • TFQTL2 antibody
    see all

Anti-HFE antibody [3F1] images

  • Anti-HFE antibody [3F1] (ab125156) at 1/500 dilution + HFE recombinant protein

    Predicted band size : 40 kDa
  • All lanes : Anti-HFE antibody [3F1] (ab125156) at 1/500 dilution

    Lane 1 : HEK293 cell lysate
    Lane 2 : HFE-hIgGFc transfected HEK293 cell lysate


    Predicted band size : 40 kDa
  • ab125156, at 1/200 dilution, staining HFE in HepG2 cells by immunofluorescence (green). Blue: DRAQ5 fluorescent DNA dye.

References for Anti-HFE antibody [3F1] (ab125156)

ab125156 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab125156.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"